Sir:
Dr. Patterson’s group has elucidated a critical finding that
supports the role of interleukin-6 (IL-6) in the pathogenesis of
schizophrenia and autism in the context of maternal immune activation
(Smith et al 2007). Extending the three mechanisms of action by IL-6
postulated by Smith et al (2007), I hypothesize that interaction between
IL-6 and insulin systems (specifically Insulin-like Growth Factor-1 [IGF-
1]) might play a crucial role.
IGF-1 plays a significant role in fetal development (Fowden,
2003). Also, IGF-1 has neuroprotective, anti-apoptotic properties that
are crucial for optimal development of the brain (Dore et al 1997).
Interestingly, IL-6 inhibits the secretion of IGF-I and its biological
activity (de Martino et al 2000; Lazarus et al 1993). Cerebral damage in
fetal pro-inflammatory states has been associated with
high IL-6 and low IGF-1 levels (Hansen-Pupp et al 2007). These studies
support significant interaction between IL-6 and IGF-1.
Increased IL-6 (Potvin et al 2007) as well as deficient IGF-1
(Venkatasubramanian et al 2007) have been demonstrated in schizophrenia.
Autism is also associated with higher IL-6 (Jyonouchi et al 2001) and
lower IGF-1 (Riikonen et al 2006). Interestingly, maternal infection has
been shown to increase the expression of fetal pro-inflammatory genes
like IL-6 in the mouse (Liverman et al 2006). Hence, it is possible
that maternal immune activation might result in persistent over-expression
of IL-6 genes in human adolescents and adults, leading to deficient IGF-1
culminating in neurobehavioral disorders like schizophrenia and autism.
In summary, this postulate of neuro-immuno-metabolic effects of IL-6
further supports the key observations reported by Smith et al (2007).
References
de Martino M, Galli L, Chiarelli F, Verrotti A, Rossi ME, Bindi G,
Galluzzi F, Salti R, Vierucci A (2000) Interleukin-6 release by cultured
peripheral blood mononuclear cells inversely correlates with height
velocity, bone age, insulin-like growth factor-I, and insulin-like growth
factor binding protein-3 serum levels in children with perinatal HIV-1
infection. Clin Immunol 94:212-218.
Dore S, Kar S, Quirion R (1997) Insulin-like growth factor I protects
and rescues hippocampal neurons against beta-amyloid- and human amylin-
induced toxicity. Proc Natl Acad Sci U S A 94:4772–4777.
Fowden AL (2003) The insulin-like growth factors and feto-placental
growth. Placenta 24:803-812.
Hansen-Pupp I, Hellström-Westas L, Cilio CM, Andersson S, Fellman V,
Ley D (2007) Inflammation at birth and the insulin-like growth factor
system in very preterm infants. Acta Paediatr 96:830-836.
Jyonouchi H, Sun S, Le H (2001) Proinflammatory and regulatory
cytokine production associated with innate and adaptive immune responses
in children with autism spectrum disorders and developmental regression. J
Neuroimmunol 120:170-179.
Lazarus DD, Moldawer LL, Lowry SF (1993) Insulin-like growth factor-1
activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha,
and interleukin-6. Lymphokine Cytokine Res 12:219-223.
Liverman CS, Kaftan HA, Cui L, Hersperger SG, Taboada E, Klein RM,
Berman NE (2006) Altered expression of pro-inflammatory and developmental
genes in the fetal brain in a mouse model of maternal infection. Neurosci
Lett 399:220-225.
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2007)
Inflammatory Cytokine Alterations in Schizophrenia: A Systematic
Quantitative Review. Biol Psychiatry [Epub ahead of print]
Riikonen R, Makkonen I, Vanhala R, Turpeinen U, Kuikka J, Kokki H
(2006) Cere brospinal fluid insulin-like growth factors IGF-1 and IGF-2 in
infantileautism.Dev Med Child Neurol 48:751-755.
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal
immune activation alters fetal brain development through interleukin-6. J
Neurosci 27:10695-10702.
Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN,
Thirthall J, Gangadhar BN, Shetty KT (2007) Insulin and insulin-like
growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J
Psychiatry 164:1557-1560.